BRCA genes: Lessons learned from experimental and clinical cancer

Annals of Oncology

Volumn 22, Issue SUPPL. 1, 2011, Pages

  Muggia, F ^a   Safra, T ^a   Dubeau, L ^b  

^a NEW YORK UNIVERSITY   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

BRCA1; BRCA2; Cisplatin; Endometrioid; Granulosa cell; Kras; Ovarian; p53; PTEN; Serous; Stem cells

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; PLATINUM COMPLEX; PROTEIN P53;

ARTICLE; BREAST ADENOCARCINOMA; CANCER GENETICS; CANCER RECURRENCE; CANCER SURGERY; CANCER SUSCEPTIBILITY; CARCINOGENESIS; DRUG CYTOTOXICITY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; GENE; GENE DELETION; GENE FUNCTION; GENE MUTATION; GENE SILENCING; GENETIC SUSCEPTIBILITY; GRANULOSA CELL; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MENSTRUATION DISORDER; NONHUMAN; ONCOGENE; ONCOGENE K RAS; ONCOGENE PTEN; OVARY CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; RISK REDUCTION; TUMOR SUPPRESSOR GENE; UTERINE TUBE CARCINOMA;

EID: 79551653347     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq659     Document Type: Article

References (29)

1. Chen JJ, Silver D, Cantor S et al. BRCA1, BRCA2, and Rad51 operate in a common DNA damage response pathway. Cancer Res 1999; 59(7 Suppl): 1752s-1756s.
2. Scully R, Livingston DM. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408: 429-432.
3. Silver DP, Dimitrov SD, Feunteun J et al. Further evidence for BRCA1 communication with the inactive X chromosome. Cell 2007; 128: 991-1002.
4. Livingston DM, Silver DP. Cancer: crossing over to drug resistance Nature 2008; 451: 1111-1115.
5. Crum CP, Drapkin R, Miron A et al. The distal Fallopian tube: a model for pelvic serous carcinogenesis. Curr Opin Obstet Gynec 2007; 19: 3-9.
6. Levanon K, Ng V, Piao HY et al. Primary ex vivo cultures of human Fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 2010; 29: 1103-1113.
7. Dubeau L. The cell of origin of ovarian epithelial tumours. Lancet 2008; 9: 1191-1197.
8. Fasano J, Muggia F. Breast cancer arising in a BRCA-mutated background: therapeutic implications from an animal model and drug development. Ann Oncol 2008; 4: 609-614.
9. Borst P, Rottenberg S, Jonkers J. How do real tumors become resistant to cisplatin? Cell Cycle 2008; 7: 1353-1359.
10. Muggia F. BRCA-deficient animal models and cisplatin resistance. Ann Oncol 2009; 20: 962.
11. Rottenberg S, Mygren AOH, Pajic M et al. Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer. Proc Natl Acad Sci USA 2007; 104: 12117-12122.
12. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
13. Chappuis PO, Goffin J, Wong N et al. A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 2002; 39: 608-610.
14. Kennedy RD, Quinn JE, Mullan PB et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 2004; 96: 1659-1668.
15. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 2009; 112: 275-281.
16. Ashworth AA. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785-3790.
17. Dinulescu DM, Ince TA, Quade BJ et al. Role of k-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11: 63-70.
18. Martzuk MM. News and views: gynecologic diseases get their genes. Nat Med 2005; 11: 24-26.
19. Paraskar AS, Shivani S, Chin KT et al. Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci 2010; 107: 12435-12440.
20. Szotek PP, Pieretti-VonMarckeMasiakos R, Masiakos PT et al. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc Natl Acad Sci USA 2006; 103: 11154-11159.
21. Saal LH, Gruvberger-Sall SK, Persson C et al. Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 2008; 40: 102-107.
22. Vang R, Shir I-M, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 2009; 16: 267-282.
23. Mangia A, Malfettone A, Simoni G, Darvishian F. Old and new concepts in histopathological characterization of familial breast cancer. Ann Oncol 2011; 22(Suppl1): mdq662.
24. Chodankar R, Kwang S, Sangiorgi F et al. Cell-nonautonomous induction of ovarian and uterine serous cystadenomas in mice lacking a functional Brca1 in ovarian granulosa cells. Curr Biol 2005; 15: 561-565.
25. Matalliotakis IM, Cakmak H, Fragouli YG et al. Epidemiological characteristics in women with and without endometriosis in the Yale series. Arch Gynecol Obstet 2008; 277: 389-393.
26. Milne RL, Antoniou AC. Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers. Ann Oncol 2011; 22 (Suppl 1): mdq660.
27. Radice P, De Summa S, Caleca L, Tommasi S. Unclassified variants in BRCA genes: guidelines for interpretation. Ann Oncol 2011; 22 (Suppl 1): mdq661.
28. Warner E. Impact of MRI surveillance and breast cancer detection in young women with BRCA mutations. Ann Oncol 2011; 22 (Suppl 1): mdq665.
29. Smith J, Axelrod D, Singh B, Kleinberg D. Prevention of breast cancer: the case for studying inhibition of IGF-1 actions. Ann Oncol 2011; 22 (Suppl 1): mdq666.